Analysts See $-1.34 EPS for Clovis Oncology, Inc. (CLVS)

April 20, 2018 - By Louis Casey

Clovis Oncology, Inc. (NASDAQ:CLVS) LogoInvestors sentiment decreased to 1.05 in 2017 Q4. Its down 0.39, from 1.44 in 2017Q3. It is negative, as 35 investors sold Clovis Oncology, Inc. shares while 69 reduced holdings. 31 funds opened positions while 78 raised stakes. 49.09 million shares or 3.43% more from 47.46 million shares in 2017Q3 were reported.
Iguana Healthcare Ltd Liability Corporation holds 2.66% or 60,000 shares. Swiss Bank & Trust reported 0.01% stake. Parametric Ltd invested in 31,335 shares. Bb&T Secs Limited Liability Company owns 4,025 shares for 0% of their portfolio. Brown Brothers Harriman & accumulated 63 shares or 0% of the stock. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS). Guggenheim Limited Liability Co holds 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS) or 52,593 shares. 5,000 were accumulated by Birchview Capital Limited Partnership. Rock Springs Cap Management Limited Partnership reported 231,500 shares or 0.71% of all its holdings. Deutsche Savings Bank Ag, Germany-based fund reported 243,628 shares. Palo Alto Invsts Limited Liability reported 9.97% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). The Norway-based Sector Gamma As has invested 1.73% in Clovis Oncology, Inc. (NASDAQ:CLVS). Kazazian Asset Mgmt Lc holds 1.36% or 19,517 shares. Cap Fund invested in 50,471 shares or 0.02% of the stock. Aperio Grp Inc Ltd Com has 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 5,073 shares.

Since December 15, 2017, it had 0 insider purchases, and 7 insider sales for $1.64 million activity. $177,480 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) was sold by IVERS-READ GILLIAN C on Tuesday, January 16.

Analysts expect Clovis Oncology, Inc. (NASDAQ:CLVS) to report $-1.34 EPS on May, 2.They anticipate $0.01 EPS change or 0.75 % from last quarter’s $-1.33 EPS. After having $-1.27 EPS previously, Clovis Oncology, Inc.’s analysts see 5.51 % EPS growth. The stock decreased 2.36% or $1.21 during the last trading session, reaching $50.11. About 1.14M shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 21.43% since April 20, 2017 and is downtrending. It has underperformed by 32.98% the S&P500.

Clovis Oncology, Inc. (NASDAQ:CLVS) Ratings Coverage

Among 9 analysts covering Clovis Oncology (NASDAQ:CLVS), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Clovis Oncology had 14 analyst reports since October 23, 2017 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Buy” rating in Friday, March 23 report. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Hold” rating by RBC Capital Markets on Thursday, November 2. The firm earned “Hold” rating on Friday, March 23 by Oppenheimer. Credit Suisse maintained it with “Buy” rating and $86.0 target in Thursday, January 18 report. The firm earned “Outperform” rating on Thursday, February 22 by Evercore. The firm has “Overweight” rating by Morgan Stanley given on Thursday, November 2. Leerink Swann maintained the shares of CLVS in report on Wednesday, November 15 with “Buy” rating. Stifel Nicolaus maintained Clovis Oncology, Inc. (NASDAQ:CLVS) rating on Tuesday, February 27. Stifel Nicolaus has “Buy” rating and $110 target. The firm has “Overweight” rating given on Tuesday, February 27 by Barclays Capital. The rating was maintained by Leerink Swann with “Buy” on Monday, February 5.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $2.53 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.